Loading...
•
Dec 31, 2021
Verastem Q4 2021 Earnings Report
Verastem Oncology secured a credit facility and reported cash balance.
Key Takeaways
Verastem Oncology announced a credit facility with Oxford Finance LLC for up to $150 million to support the development and potential launches of VS-6766 and defactinib. The company's cash, cash equivalents, and investment balance was $100.3 million as of December 31, 2021, and pro-forma balance would have been $125.3 million after initial drawdown.
Verastem Oncology secured up to $150 million in non-dilutive funding from Oxford Finance LLC.
Initial $25 million term loan was drawn at closing.
Company had cash, cash equivalents, and investment balance of $100.3 million as of December 31, 2021.
Expected cash runway through 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...